Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
29 November 2023
In the News
Daljit Doogal Discusses Foley’s Strategic Growth and Big Law Expansion Trends in Emerging Legal Markets
Foley & Lardner LLP Chairman and CEO Daljit Doogal is quoted in The American Lawyer article, “Big Fish, Small Ponds: How Big Law Is Slowly Infiltrating Emerging Markets,” offering insight on Foley’s continued national growth and Big Law expansion trends.
28 November 2023
In the News
Kyle Faget Discusses Coverage and Reimbursement for Telehealth Services
Foley & Lardner LLP partner Kyle Faget is interviewed by Healthcare IT Today in the article, “What’s a Problem, Technology, Opportunity, or Issue That Not Enough People are Talking About?”
22 November 2023
In the News
Naikang Tsao Assesses Copyright Act’s Fair Use Defense After Warhol Foundation v. Goldsmith
Foley & Lardner LLP partner Naikang Tsao authored the Westlaw Today article, “Still too subjective: the Copyright Act’s fair use defense after Andy Warhol Foundation v. Goldsmith.”